Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
J Inherit Metab Dis ; 20(4): 517-24, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9266387

ABSTRACT

Ornithine transcarbamylase deficiency shows X-linked inheritance with partial dominant expression in carrier females. We studied a girl with intermittent severe orotic aciduria and mild hyperammonaemia despite apparently normal enzyme activity in the liver. Sequence analysis of all 10 exons of the ornithine transcarbamylase gene revealed a novel A-->G exchange (A502G) in exon 5 which changes His-136 to arginine in the ornithine transcarbamylase protein. Km values for carbamyl phosphate and ornithine determined in the patient's liver were comparable to those of wild-type enzyme but, unlike the wild-type enzyme, the mutant enzyme was unstable upon freezing and thawing. Electron microscopy revealed several giant mitochondria with paracrystalline inclusions. The results are compatible with the assumption that the mutant enzyme cannot form a functional complex with carbamyl phosphate synthetase and the ornithine carrier, resulting in decreased availability of substrates and diminished enzyme activity in vivo.


Subject(s)
Mutation , Ornithine Carbamoyltransferase/genetics , Orotic Acid/urine , Ammonia/blood , Child , Female , Humans , Infant , Kinetics , Liver/enzymology , Liver/ultrastructure , Microscopy, Electron , Mitochondria, Liver/enzymology , Mitochondria, Liver/ultrastructure , Ornithine Carbamoyltransferase/metabolism , Polymerase Chain Reaction , Proteins/metabolism
3.
Vaccine ; 7(5): 457-61, 1989 Oct.
Article in English | MEDLINE | ID: mdl-2479187

ABSTRACT

A Plasmodium falciparum sporozoite vaccine, composed of a synthetic dodecapeptide (NANP)3 coupled to tetanus toxoid (TT), was injected, at weeks 0 and 8, into non-immune volunteers in two randomized double-blind placebo-controlled trials. In the first trial, 37 volunteers received the vaccine simultaneously with placebo (group 1), 0.5 x 10(6-) (group 2), or 1.5 x 10(6) U (group 3) of recombinant human interferon-alpha (= IFN-alpha). In the second trial, 35 other volunteers received the vaccine with placebo (group 4), 0.25 x 10(6) (group 5), or 1.0 x 10(6) IU (group 6) of interferon-gamma (= IFN-gamma). Immunizations were well tolerated and resulted in seroconversion rates (greater than or equal to 4-fold increase of antibody titre in immunofluorescence or enzyme-linked immunosorbent assays) of 67-100% of volunteers. IFN-alpha significantly enhanced the IgG antibody titres in ELISA to malaria peptide.


Subject(s)
Adjuvants, Immunologic , Antibodies, Protozoan/biosynthesis , Interferons/immunology , Oligopeptides/immunology , Plasmodium falciparum/immunology , Vaccines, Synthetic/immunology , Vaccines/immunology , Adult , Animals , Double-Blind Method , Enzyme-Linked Immunosorbent Assay , Female , Fluorescent Antibody Technique , Humans , Immunoglobulin G/biosynthesis , Lymphocyte Activation , Male , Middle Aged , Oligopeptides/administration & dosage , Randomized Controlled Trials as Topic , Tetanus Toxoid , Vaccines, Synthetic/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...